System A neutral amino acid transporter regulation by interleukin-1beta in human osteoarthritic synovial cells: evidence for involvement of prostaglandin E(2) as a second messenger

J Cell Physiol. 2000 Apr;183(1):65-73. doi: 10.1002/(SICI)1097-4652(200004)183:1<65::AID-JCP8>3.0.CO;2-H.

Abstract

We studied the long-terms effects of interleukin-1beta (IL-1beta; 3 to 6 h) on alpha-(methylamino) isobutyric acid (MeAIB), a nonmetabolizable amino acid transported by system A. We found that IL-1beta induced a large decrease in MeAIB uptake by human osteoarthritic synovial cells and a concomitant increase in prostaglandin E(2) (PGE(2)) synthesis. Therefore, we investigated whether PGE(2) acts as a mediator for the long-term action of IL-1beta. We found that exogenous PGE(2) inhibited MeAIB uptake, and that AH6809, a PGE(2) receptor antagonist, inhibited IL-1beta-mediated MeAIB uptake. To identify the enzymes involved in the IL-1beta-mediated synthesis of PGE(2) that inhibits MeAIB uptake, we studied the expression of secreted (s) and cytosolic (c) phospholipase A(2) (PLA(2)). Because both were expressed, we selected a broad spectrum of inhibitors to determine which of the two PLA(2)s was involved. We used AACOCF3, a cPLA(2) inhibitor, and dithiothreitol (DTT) and bromophenacyl bromide (BPB), which are sPLA(2) inhibitors. Our results suggest that the PLA(2) involved in the IL-1beta-mediated synthesis of PGE(2) was sPLA(2). We also showed the expression of cyclooxygenase (COX)-2 and its partial involvement using a potent selective COX-2 inhibitor, L-745337. These findings provide insight into the mechanisms underlying the IL-1beta-mediated regulation of transport system A. The Il-1beta-induced inhibition of MeAIB uptake in human osteoarthritic synovial cells thus seems to be essentially mediated by PGE(2) production via the activation of sPLA(2) and the partial activation of COX-2.

MeSH terms

  • Amino Acid Transport Systems
  • Arachidonic Acids / pharmacology
  • Biological Transport / drug effects
  • Carrier Proteins / drug effects
  • Carrier Proteins / metabolism*
  • Cells, Cultured
  • Cyclooxygenase 2
  • Cytosol / enzymology
  • Dinoprostone / physiology*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Gene Expression Regulation, Enzymologic / drug effects
  • Humans
  • Indans / pharmacology
  • Interleukin-1 / pharmacology*
  • Isoenzymes / genetics
  • Isoenzymes / metabolism
  • Kinetics
  • Membrane Proteins
  • Osteoarthritis / pathology
  • Osteoarthritis / physiopathology*
  • Phospholipases A / genetics
  • Phospholipases A / metabolism
  • Prostaglandin-Endoperoxide Synthases / genetics
  • Second Messenger Systems / drug effects
  • Second Messenger Systems / physiology*
  • Synovial Membrane / drug effects
  • Synovial Membrane / pathology
  • Synovial Membrane / physiopathology*
  • Xanthenes / pharmacology
  • Xanthones*
  • beta-Alanine / analogs & derivatives*
  • beta-Alanine / pharmacokinetics

Substances

  • Amino Acid Transport Systems
  • Arachidonic Acids
  • Carrier Proteins
  • Enzyme Inhibitors
  • Indans
  • Interleukin-1
  • Isoenzymes
  • L 745337
  • Membrane Proteins
  • Xanthenes
  • Xanthones
  • arachidonyltrifluoromethane
  • beta-Alanine
  • 2,2-dimethyl-beta-alanine
  • 6-isopropoxy-9-oxoxanthene-2-carboxylic acid
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Phospholipases A
  • Dinoprostone